A recent research published in ‘The Lancet’ examined the adiposity in children of women with type 2 diabetes from the Metformin in Women with Type 2 Diabetes in Pregnancy (MiTy) trial, with and without in-utero exposure to metformin, up to 24 months of age.

      The follow-up study, MiTy Kids, included infants of women who participated in the MiTy randomized controlled trial, receiving either oral 1000 mg metformin twice daily or placebo. Caregivers and researchers remained masked to the type of medication (metformin or placebo) mothers received during their pregnancy. Anthropometric measurements, including weight, height, and skin fold thicknesses, were taken at 3, 6, 12, 18, and 24 months. At 24 months, linear regression was used to compare the BMI Z score and sum of skin folds in the metformin versus placebo groups, adjusted for confounders. Fractional polynomials were used to assess growth trajectories.

      There was no overall difference in BMI trajectory but, in males, trajectories were significantly different by treatment (p=0·048). BMI in the metformin group was higher between 6 and 24 months. Children of women with type 2 diabetes were approximately 1 SD heavier than the WHO reference population.